


Supplemental Figure 1. PC1-p30 stabilization is independent of PHD enzyme activity and proline hydroxylation. (A) Immunoblot of MDCK-p30 cells treated with CoCl₂ or the PHD inhibitors roxadustat, mimosine, and DMOG. HIF-1 α was used as a control for PHD-dependent stabilization. (B) Multiple sequence alignment of predicted proline hydroxylation sites in the PC1 C-terminal tail. (C) Immunoblot of MDCK cells transfected with PC1-p30 proline to alanine mutation constructs of the proline residues outlined in red in B. All proline mutation constructs were stabilized in the presence of CoCl₂ or MG132.

4107
RWRYHALRGELYRPAWEPQDYEMVELFLRRLRLWMGLSKVKEFRHKVRFEGMEPLPSRSS
RGSKVSPDVPPPSAGSDASHPSTSSSQLDGLSVSLGRLGTRCEPEPSRLQAVFEALLTQF
DRLNQATEDVYQLEQQLHSLQGRRSSRAPAGSSRGPSGLR PALPSRLARASRGVDLATG
PSRTPLRAKNKVHPSST
4303

Supplemental Figure 2. PC1-p30 ROS-dependent stabilization motif and mitochondrial targeting sequence. Human PC1-p30 sequence with the ROS-dependent stabilization motif (ROS-M) and mitochondrial targeting sequence (MTS) highlighted.



Supplemental Figure 3. PC1-p15 is cleaved from both human and mouse PC1-p30. MDCK cells were transfected with either human (**A**) or mouse (**B**) PC1-p30. PC1-p15 cleavage occurred from both human and mouse PC1-p30 in the presence of apoptosis inducers ALLN and staurosporine, and cleavage was abolished by the pan-caspase inhibitor z-VAD-fmk.